14.24
Mediwound Ltd stock is traded at $14.24, with a volume of 69,383.
It is up +0.28% in the last 24 hours and down -13.17% over the past month.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
See More
Previous Close:
$14.20
Open:
$14.4
24h Volume:
69,383
Relative Volume:
0.75
Market Cap:
$183.02M
Revenue:
$16.96M
Net Income/Loss:
$-23.88M
P/E Ratio:
-6.7907
EPS:
-2.097
Net Cash Flow:
$-20.66M
1W Performance:
+1.06%
1M Performance:
-13.17%
6M Performance:
-24.42%
1Y Performance:
-26.71%
Mediwound Ltd Stock (MDWD) Company Profile
Compare MDWD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MDWD
Mediwound Ltd
|
14.24 | 183.02M | 16.96M | -23.88M | -20.66M | -2.097 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-02-25 | Initiated | Alliance Global Partners | Buy |
| Feb-28-25 | Initiated | Craig Hallum | Buy |
| Jul-16-24 | Reiterated | Maxim Group | Buy |
| Dec-22-22 | Initiated | Maxim Group | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Sep-23-20 | Initiated | BTIG Research | Buy |
| Nov-28-16 | Initiated | Aegis Capital | Buy |
| Aug-17-16 | Initiated | Wells Fargo | Outperform |
| Apr-16-14 | Initiated | Oppenheimer | Outperform |
View All
Mediwound Ltd Stock (MDWD) Latest News
Mediwound Ltd (MDWD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mediwound Ltd (MDWD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mediwound Ltd (MDWD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mediwound Ltd (MDWD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mediwound Ltd (MDWD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mediwound Ltd (MDWD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mediwound Ltd (MDWD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mediwound Ltd (MDWD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MDWD Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentEarnings Growth Analysis - newsline.com
MDWD Q1 2026 Earnings: Strong Beat on EPS Despite Narrower LossEarnings Per Share - newsline.com
MDWD Q1 2026 Earnings: Significant EPS Beat Drives Positive Sentiment Despite Absent RevenueCost Structure Review - newsline.com
MediWound Ltd. (MDWD) Q1 2026 Earnings: Narrowed Loss Surprises to the UpsideGeographic Revenue Trends - newsline.com
MediWound (MDWD) Sheds 1.87% as Stock Holds Above Key Support LevelAccumulation Line - newsline.com
MediWound Ltd. (MDWD) Retreats 1.87% as Price Tests Support Near $13.47Wave Equality - newsline.com
(MDWD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Craig Hallum Forecasts MediWound's Q3 Earnings (NASDAQ:MDWD) - MarketBeat
Maxim Group Issues Negative Estimate for MediWound Earnings - MarketBeat
Insider Buying: Nachum Shamir Acquires 6,000 Shares of MediWound Ltd (MDWD) - GuruFocus
Director at MediWound (MDWD) buys 6,000 ordinary shares in market - Stock Titan
MediWound Ltd. Stock Plummets to New 52-Week Low of $13.58 - Markets Mojo
Insider Buying: David Fox Acquires Shares of MediWound Ltd (MDWD) - GuruFocus
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30 - Moomoo
MediWound (MDWD) director buys 3,537 ordinary shares on open market - Stock Titan
MediWound Q1 earnings call highlights - MSN
Director Rubinstein buys MediWound (MDWD) shares and holds multiple options - Stock Titan
MediWound Shares Slide This Week; BARDA Moves in Focus - Bez Kabli
MediWound Ltd. Hits New 52-Week Low at USD 14.14 - MarketsMojo
MediWound (MDWD) Slips 1.58% as Stock Holds Near Critical Support at $13.61Price Momentum Stocks - The Legal Advocate
MediWound (MDWD) Insider Trading Activity 2026 - MarketBeat
5 Stocks Better Than MediWound as Q1 Revenue Declines - HarianBasis.co
A. G. P. Maintains MediWound(MDWD.US) With Buy Rating, Cuts Target Price to $22 - Moomoo
MDWD Maintains Outperform by Oppenheimer -- Price Target Lowered to $32 - GuruFocus
MDWD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $36 - GuruFocus
Oppenheimer Adjusts MediWound Price Target to $32 From $33, Maintains Outperform Rating - Moomoo
Oppenheimer Maintains MediWound(MDWD.US) With Buy Rating, Cuts Target Price to $32 - Moomoo
Will MediWound (NASDAQ:MDWD) Spend Its Cash Wisely? - Yahoo Finance
MediWound Ltd. (NASDAQ:MDWD) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $36 - Moomoo
MediWound: Q1 Earnings Snapshot - AOL.com
MediWound Q1 2026 Earnings Call Transcript - MarketBeat
MediWound (MDWD) Q1 Loss Of US$0.23 Per Share Reinforces Bearish Profitability Narratives - simplywall.st
Q3 2025 Mediwound Ltd Earnings Call Transcript - GuruFocus
Q1 2026 Mediwound Ltd Earnings Call Transcript - GuruFocus
MediWound Ltd (MDWD) Q1 2026 Earnings Call Highlights: Strategic Collaborations and Revenue Challenges - GuruFocus
Oppenheimer lowers MediWound stock price target to $32 on revenue miss - Investing.com UK
Oppenheimer lowers MediWound stock price target to $32 on revenue miss By Investing.com - Investing.com Australia
MediWound Q1 2026 earnings preview - MSN
MediWound (MDWD) reports Q1 2026 results, reaffirms guidance - grafa.com
MediWound Q1 Earnings Call Highlights - sharewise.com
Mediwound Ltd Stock (MDWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):